President & Chief Executive Officer
Stephen A. Hurly brings nearly two decades of leadership experience in the life sciences industry. Prior to his role as president and CEO of Eleven, he joined Viventia as chief executive officer in March 2014. Previously, Mr. Hurly was the chief executive officer of Burrill & Co.'s Merchant Banking Division, a finance business for life science companies, from 2011 to 2014. Prior to that, Mr. Hurly was the head of the Life Sciences Investment Banking Practice at Boenning & Scattergood, a securities asset management and investment banking firm, from 2008 to 2011. Mr. Hurly has more than 15 years of experience in the investment banking business. Mr. Hurly currently serves on the board of directors of PHusis Therapeutics Inc., a targeted small molecule therapeutics company, since May 2011. He graduated from Swarthmore College with a B.A. degree in Engineering in 1990 and earned an M.B.A. from the University of Chicago in 1997.
Chief Scientific Officer
Gregory P. Adams, Ph.D., serves as our chief scientific officer, leading the advancement of the company's oncology pipeline of novel Targeted Protein Therapeutics. Previously, Dr. Adams was Director of Biological Research and Therapeutics at Fox Chase Cancer Center from 2013 to 2015, where he led a laboratory group focused on developing antibodies and antibody-drug conjugates for the treatment of breast, ovarian and renal cancer. Earlier at Fox Chase Cancer Center, Dr. Adams co-lead the Center's Developmental Therapeutics Program from 2009 to 2013. Dr. Adams serves on the Editorial Boards of Cancer Immunology Research, MAbs and Cancer Biotherapy & Radiopharmaceuticals. He is a member of the Integration Panel of the U.S. Department of Defense's Breast Cancer Research Program and recently completed a four-year term as a member of the U.S. National Cancer Institute's Cancer Immunopathology and Immunotherapy Study Section. He was a co-founder of a computational antibody design company, RAbD Biotech, and has served on the Scientific Advisory Boards of a number of biotechnology companies including Endo Pharmaceuticals Inc., Symphogen A/S, Avipep Pty. Ltd., AvidBiologics (now known as Formation Biologics, Inc.) and YM Biosciences Inc. (which was acquired by Gilead Sciences, Inc.). He graduated from the University of California, Santa Cruz with a Bachelor's Degree in Biology in 1983 and earned a Ph.D. in Immunology from the University of California at Davis in 1991.
SVP, Clinical Development
David is Sr. Vice President of Clinical Development at Eleven Biotherapeutics and Medical Monitor for the VISTA Phase 3 study of Vicinium in Non-Muscle Invasive Bladder Cancer. Prior to this David spent 13 years in roles of increasing of increasing responsibility in clinical research and translational medicine at Deciphera, Astra Zeneca, Tesaro, Abraxis and Merck. This includes development of oncology experimental therapeutics from pre-IND through late phase development as well as biomarker and diagnostics development. He trained in Internal Medicine and Medical Genetics at Penn and CHOP respectively becoming an Instructor in the Division of Medical Genetics at Hospital of the University of Pennsylvania in 2000. After pursuing a BA in Molecular, Cellular and Developmental Biology at The University of Colorado in Boulder, David completed the MD/PhD program at Cornell and Sloan-Kettering. David is a passionate advocate for immuno and targeted therapies in precision cancer medicine.
Chief Technology Officer
Glen C. MacDonald, Ph.D., serves as our chief technology officer. Previously, Dr. MacDonald served our predecessor company in several research related capacities from 1997 to 2005. Prior to joining us, Dr. MacDonald held a Manitoba Cancer Treatment Research Foundation Fellowship from 1996 to 1997 while serving as a Post-Doctoral Fellow at the University of Manitoba Cancer Treatment Research Foundation from 1995 to 1997. Dr. MacDonald also served as a Canadian Arthritis Society Post-Doctoral Fellow at the University of North Carolina at Chapel Hill from 1993 to 1995. He graduated from the University of Guelph with a Bachelor’s Degree in Genetics in 1980 and earned an M.Sc. and Ph.D. from the University of Manitoba in 1987 and 1993, respectively. Dr. MacDonald’s scientific background is extensive, having published in the areas of monoclonal antibodies, graft versus-host disease, lupus and apoptosis.
Chief Financial Officer
John McCabe brings more than 20 years of finance and accounting experience to Eleven. Prior to joining Eleven, he was Vice President of Finance at Clinical Data, Inc., a drug developer that was acquired by Forest Laboratories after FDA approval of its lead drug product for depression, Viibryd®. Prior to that, Mr. McCabe served in several financial roles at Interleukin Genetics, Inc., a genetics-focused personalized health company; and SatCon Technology Corporation, a developer of innovative power conversion solutions. John began his career working for the accounting firm of Coopers & Lybrand LLP, now known as PricewaterhouseCoopers LLP. He received a B.S. in Business Administration from the University of Vermont and is also a Certified Public Accountant.